Published in Vaccine Weekly, February 2nd, 1998
"To our knowledge, this is the first demonstration of protection against malaria by a synthetic peptide vaccine designed to induce CD8+ CTL responses against a single class I-restricted CTL epitope," wrote Eileen D. Franke, Naval Medical Research Institute, Malaria Program, Rockville, Maryland, and colleagues ("Induction of Protective CTL Responses against the Plasmodium yoelii circumsporozoite Protein by Immunization with Peptides," the Journal of Immunology, 1997;159:3424-3433).
The study was designed to determine the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.